Mutations in the CALR gene have been discovered in 50–80% of ET or PMF patients without mutations of the JAK2 or MPL genes,5, 6 indicating that this discovery is a further important step in the improvement of the diagnostic and characterisation of MPNs and for the application of kinase inhibitor therapy. This evidence concerns the gene MPL and essential thrombocythemia.